Discover 3 typical patient phenotypes: these hypertensive patients presenting with different symptoms (heart failure, atrial fibrillation and renal insufficiency) will be discussed throughout Course sessions. This week, Patient #3 with renal insufficiency is revealed!
"Percutaneous renal denervation in a drug-naive patient with multiple intolerances to antihypertensive agents reduced office and ambulatory blood pressure" Discover this new case and say how you would treat.
Michael Böhm (University of Saarland, Homburg/Saar, Germany) co-chairman of the Global SYMPLICITY Registry presented today during the late-breaking clinical trial session at the 63rd Scientific Sessions of the American College of Cardiology (ACC) the six month analysis of the first 1,000 patients enrolled in the open-label real-world patient registry. The Global SYMPLICITY Registry continues to demonstrate the safety of renal denervation with the Symplicity™ renal denervation system.
Simultaneously to the presentation of Deepak L. Bhatt (Brigham and Women's Hospital, Boston, MA) in the Late-Breaking Clinical Trials session, 63rd Scientific Sessions of the American College of Cardiology (ACC) 2014 in Washington D.C., the results are now published online in The New England Journal of Medicine.
RHC 2014 - Discover the presentations from the third session.
Download the slides if you would like to learn more about “personalised medicine” and the different possible antihypertensive drug combinations for the three “fil rouge” patients with elevated blood pressure: an elderly atherosclerotic patient, a metabolic patient and a young adrenergic patient.
RHC 2014 - Discover the presentations from the second session.
Download the slides if you would like to understand how to systematically evaluate a patient with uncontrolled hypertension. The session comprehensively discusses the different modalities to measure blood pressure, assess the personalised patient risks, and it also includes key data for drug adherence.